WuXi XDC uses a special light protection label from Schreiner MediPharm for a clinical cancer study. In the current clinical trial for a novel antibody drug conjugate (ADC), a label is now being used that offers light protection and at the same time blinds the preparation.
To support a biotech company in a clinical trial for an ADC drug, WuXi XDC needed a reliable labelling solution. The light-sensitive active ingredient is filled into vials as a lyophilised powder and must be effectively protected from external influences. WuXi XDC, in collaboration with Schreiner MediPharm the right solution by offering a Light-Protect-Label which perfectly met the specific customer requirements.
Schreiner MediPharm developed a solution with integrated UV and light protection, perfect for transparent vials is suitable. The opaque label completely encloses the vessel and offers optimum light protection. At the same time, it supports the safe conduct of the clinical trial by reliably blinding the investigational medicinal products. A Resealable viewing window allows an unadulterated view of the vial contents. This is crucial for checking the condition and colour of the reconstituted lyophilisate before administration and thus ensuring the efficacy of the medication.
The innovative label-integrated light protection solution from Schreiner MediPharm was customised to the specific application and the corresponding container. The pharmaceutical expert can draw on its extensive expertise in materials, adhesives and printing techniques as well as comprehensive tests on light protection properties. WuXi XDC therefore benefits from an efficient, multifunctional solution, which combines the protection of the light-sensitive active ingredient with safe blinding during the clinical trial. This optimises processes, speeds up the process of clinical trials and supports product and patient safety.
The light protection solution from Schreiner MediPharm can be used perfectly for antibody-drug conjugates, as in this study. These represent a significant innovation in cancer therapy. Through the targeted introduction of drugs into specific tumour cells, they enable gentler and more effective treatment compared to conventional chemotherapies. This technology acts directly on the cancer cell, largely sparing healthy cells and minimising side effects.
Source: Schreiner MediPharm
